Global Custom Market Research Reports Provider Company

phone

Global Soft Tissue Sarcoma Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

  • Published Date: 01 Nov 2017
  • Number of Pages: 220
  • Category: Healthcare and Medical
  • Country: Global
Global Soft Tissue Sarcoma Treatment Market:

Global soft tissue sarcoma treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for soft tissue sarcoma treatment projected to reach US$ XX Mn by 2023.

Soft tissue sarcoma is the rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develop from fat cells, and leiomyosarcomas, which arise from smooth muscle tissue. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumour. If surgical procedure is not required, chemotherapy alone can be used.

Increase in the prevalence and incidence of different types of cancers, rise in the number of soft tissue sarcoma cases, increase in the R&D activities on drugs and other biological therapies, patent expiry of branded drugs, increase in the healthcare expenditure and rise in quality patient care are expected to fuel the soft tissue sarcoma treatment market over the forecast period. However, high cost for the radiotherapy and chemotherapy, stringent regulatory guidelines, and adverse effects associated with the treatment might hinder the growth of soft tissue sarcoma treatment market over the forecast timeframe.

The soft tissue sarcoma treatment market has been segmented on basis of disease type, treatment type, and end user

Based on the treatment type, soft tissue sarcoma treatment market is segmented into following:

Targeted Therapy
Chemotherapy
Anti-angiogenesis drugs
Radiation Therapy
Internal Radiation Therapy
External Radiation Therapy

Based on the disease type, soft tissue sarcoma treatment market is segmented into following:

Local Sarcoma
Regional Sarcoma
Metastatic Sarcoma

Based on the distribution channel, soft tissue sarcoma treatment market is segmented into following:

Hospitals
Oncology Clinics
Long Term Care Centres

Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all evofosfamide development expenses. GSKs Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Geographically, soft tissue sarcoma treatment market segmented into following regions Viz. North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America may lead the soft tissue sarcoma treatment market owing to increase in the prevalence of the disease. According to American Cancer Society, approximately 12,390 people in 2016 are suffering soft tissue sarcoma and cancer. Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. Asia-Pacific region accounts for a significant growth due to increase in cancer cases, and rise in awareness about advanced soft tissue sarcoma treatment.

Some of the players in the soft tissue sarcoma treatment market are GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) to name a few.

In October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Companys drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types soft tissue carcinoma

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitors overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startups details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Publisher Name : Precision Business Insights
1. Executive summary
2. Global Soft Tissue Sarcoma Treatment Market Introduction
2.1. Global Soft Tissue Sarcoma Treatment Market Taxonomy
2.2. Global Soft Tissue Sarcoma Treatment Market Definitions
2.2.1. Treatment Type
2.2.2. Distribution Channel
3. Global Soft Tissue Sarcoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Soft Tissue Sarcoma Treatment Market Dynamics Factors Impact Analysis
3.6. Global Soft Tissue Sarcoma Treatment Market Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.7. Global Soft Tissue Sarcoma Treatment Market Recent Treatment Launches
4. Global Soft Tissue Sarcoma Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 2023
4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Soft Tissue Sarcoma Treatment Market, By Treatment Type, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Targeted Therapy
5.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Chemotherapy
5.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Anti-angiogenesis Drugs
5.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Radiation Therapy (Internal Radiation Therapy and External Radiation Therapy)
5.4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Soft Tissue Sarcoma Treatment Market, By Disease Type, 2012 - 2016 and Forecast, 2017 - 2023
6.1. Local Sarcoma
6.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Regional Sarcoma
6.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Metastatic Sarcoma
6.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Soft Tissue Sarcoma Treatment Market Forecast, By Distribution Channel, 2012 - 2016 and Forecast, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Long-Term Care Centers
7.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Soft Tissue Sarcoma Treatment Market Forecast, By Region, 2012 - 2016 and Forecast, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Region, 2017 2023
9. North America Soft Tissue Sarcoma Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.1.1. Treatment Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Targeted Therapy
9.1.1.2. Chemotherapy
9.1.1.3. Anti-angiogenesis drugs
9.1.1.4. Radiation Therapy
9.1.1.4.1. Internal Radiation Therapy
9.1.1.4.2. External Radiation Therapy
9.1.2. Disease Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Local Sarcoma
9.1.2.2. Regional Sarcoma
9.1.2.3. Metastatic Sarcoma
9.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Long-Term Care Centers
9.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 2023
9.1.6. North America Soft Tissue Sarcoma Treatment Market Dynamics Trends
10. Europe Soft Tissue Sarcoma Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Treatment Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Targeted Therapy
10.1.1.2. Chemotherapy
10.1.1.3. Anti-angiogenesis drugs
10.1.1.4. Radiation Therapy
10.1.1.4.1. Internal Radiation Therapy
10.1.1.4.2. External Radiation Therapy
10.1.2. Disease Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Local Sarcoma
10.1.2.2. Regional Sarcoma
10.1.2.3. Metastatic Sarcoma
10.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Long-Term Care Centers
10.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 2023
10.1.6. Europe Soft Tissue Sarcoma Treatment Market Dynamics Trends
11. Asia-Pacific Soft Tissue Sarcoma Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
11.1.1. Treatment Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Targeted Therapy
11.1.1.2. Chemotherapy
11.1.1.3. Anti-angiogenesis drugs
11.1.1.4. Radiation Therapy
11.1.1.4.1. Internal Radiation Therapy
11.1.1.4.2. External Radiation Therapy
11.1.2. Disease Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Local Sarcoma
11.1.2.2. Regional Sarcoma
11.1.2.3. Metastatic Sarcoma
11.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Long-Term Care Centers
11.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 2023
11.1.6. Asia-Pacific Soft Tissue Sarcoma Treatment Market Dynamics Trends
12. Latin America Soft Tissue Sarcoma Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
12.1.1. Treatment Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Targeted Therapy
12.1.1.2. Chemotherapy
12.1.1.3. Anti-angiogenesis drugs
12.1.1.4. Radiation Therapy
12.1.1.4.1. Internal Radiation Therapy
12.1.1.4.2. External Radiation Therapy
12.1.2. Disease Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Local Sarcoma
12.1.2.2. Regional Sarcoma
12.1.2.3. Metastatic Sarcoma
12.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Long-Term Care Centers
12.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 2023
12.1.6. Latin America Soft Tissue Sarcoma Treatment Market Dynamics Trends
13. Middle East & Africa Soft Tissue Sarcoma Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
13.1.1. Treatment Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Targeted Therapy
13.1.1.2. Chemotherapy
13.1.1.3. Anti-angiogenesis drugs
13.1.1.4. Radiation Therapy
13.1.1.4.1. Internal Radiation Therapy
13.1.1.4.2. External Radiation Therapy
13.1.2. Disease Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Local Sarcoma
13.1.2.2. Regional Sarcoma
13.1.2.3. Metastatic Sarcoma
13.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Long-Term Care Centers
13.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 2023
13.1.6. MEA Soft Tissue Sarcoma Treatment Market Dynamics Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Treatment & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. GlaxoSmithKline plc (U.K.)
14.2.2. Eli Lilly and Company (U.S.)
14.2.3. Pfizer, Inc. (U.S.)
14.2.4. Bristol-Myers Squibb (U.S.)
14.2.5. F. Hoffmann-La Roche AG (Switzerland)
14.2.6. Johnson & Johnson Services, Inc. (U.S.)
14.2.7. Teva Pharmaceutical Industries Ltd (Israel)
14.2.8. Celgene Corporation (U.S.)
15. Research Methodology
16. Key Assumptions and Acronyms


MRC Global Inc (MRC) is a provider of pipe, valves and fittings. Its product portfolio include carbon steel pipe, carbon steel fittings and flanges, valve automation, stainless and alloy pipe,

View Report

This report studies Wheelchair Accessible Vehicle Converters in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these

View Report

This report studies Swimwear and Beachwear in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions,

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports